RapidPulse: Medtronic’s Next Bet in Stroke

An oversubscribed $48 million Series B announced on July 16th offers a revealing look at where the neurovascular thrombectomy market may be heading.

Miami-based RapidPulse is developing a next-generation pulsed-aspiration catheter designed to remove blood clots during acute ischemic stroke. But the most notable part of the financing may be who helped lead it: Medtronic.

Rather than waiting for the technology to reach the market, Medtronic invested alongside co-leads TechWald Next and S3 Ventures. SBI Investment and the Florida Opportunity Fund also participated, joining existing investors Santé Ventures, Syntheon, Hatteras Venture Partners, and Epidarex Capital. The financing will support RapidPulse’s TURBO investigational device trial.

For an established neurovascular leader, the investment creates an early position in a technology that could become increasingly important to the stroke market.

The Numbers

Approximately 795,000 strokes occur annually in the U.S., with ischemic strokes representing roughly 87% of the total. Within that population, large-vessel occlusion (LVO) represents a critical target for mechanical thrombectomy because rapidly restoring blood flow can significantly influence patient outcomes.

The market surrounding these procedures continues to expand. Global neurovascular thrombectomy device sales reached approximately $830 million in 2025 and are projected to approach $1.14 billion by 2030, representing a mid-single-digit CAGR.

Medtronic, Stryker, and Penumbra anchor the competitive landscape. Penumbra has generated as much as $321 million in a single quarter from its aspiration catheter business, while Stryker’s $4.9 billion acquisition of Inari Medical in February 2025 strengthened its position in thrombectomy.

Medtronic is hardly entering unfamiliar territory. Its neurovascular portfolio already includes the Solitaire stent retriever and React aspiration catheter, supported by an established commercial presence in hospital neuro-interventional suites.

That context makes the Series B particularly interesting. Medtronic is not investing to gain exposure to stroke. It is securing an early position in a potential next-generation technology for a market where it already has products, customers, and distribution.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/rapidpulse-medtronics-next-bet-in-stroke 

Comments

Post a Comment

Popular posts from this blog

U.S. Medtech Market Growth: The Numbers Behind the Trends

The U.S. medtech market continues to be a dominant force globally, representing over 45% of the worldwide medtech revenue as of 2025. Despite recent concerns and headlines suggesting uncertainty, a deeper dive into the numbers tells a different story: one of resilience and steady expansion. Thanks to growing  surgical procedure volumes  and significant investments in innovation, the United States remains at the forefront of medtech development. In this article, we’ll explore the factors driving growth, key statistics, and the market’s long-term outlook for  medtech companies . U.S. Medtech Market Resilience Amidst Challenges For the past several decades, the United States has remained the largest market for medical devices worldwide. Its dominance in the field is attributed to several factors: a robust ecosystem of research and development, a highly engaged healthcare workforce, and the adoption of cutting-edge technologies like surgical robotics and AI-powered diagnostic...
Read more

The Weekly Recap 4/11/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

  Achieved ISO 13485 certification, the globally recognized standard for quality management systems for medical devices. The accreditation strengthens the company’s manufacturing readiness for its 4Degra bioabsorbable resin platform, supporting its commercial strategy and accelerating regulatory pathways toward clinical deployment. For more information visit here:  https://medium.com/@lifesciencemarketresearch/the-weekly-recap-4-11-25-lsi-alumni-achievements-driving-medtech-and-healthtech-forward-386e389bab3a
Read more

LSI Alumni Innovator Spotlight: CardiaCare CEO Amir Soltanianzadeh

Soltanianzadeh’s medtech journey has taken him from start-up entrepreneur, to investor, to CEO of CardiaCare: an innovative AI-based neuromodulation therapy company working to revolutionize atrial fibrillation treatment. In the midst of a Series A raise, he will be presenting at the March LSI USA ‘25 event in Dana Point, CA. For more information visit here:  https://mega.nz/file/LTxAHJII#mNylAswp3i9PhxvgGpM2f_pQtN9BnWR5z9rQQK2cluU  
Read more